Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Malignant Melanoma

Free Subscription Articles published in Ann Surg Oncol Retrieve available abstracts of 172 articles: HTML format

Single Articles

November 2025
1. BREEZE S, Peterson C, Garioch J, Nobes J, et al
   ASO Visual Abstract: A Simplified Classification System For In-Transit Melanoma Metastases.
   Ann Surg Oncol. 2025 Nov 18. doi: 10.1245/s10434-025-18722.
   PubMed    
   
   
   
2. BREEZE S, Peterson C, Garioch J, Nobes J, et al
   A Simplified Classification System for In-Transit Melanoma Metastases.
   Ann Surg Oncol. 2025 Nov 10. doi: 10.1245/s10434-025-18542.
   PubMed     Abstract available
   
   
   
3. BREEZE S, Peterson C, Moncrieff M
   ASO Author Reflections: A Simplified Classification System for In-Transit Melanoma Metastases.
   Ann Surg Oncol. 2025 Nov 4. doi: 10.1245/s10434-025-18657.
   PubMed    
   
   
   
4. ROBINSON TP, Kaiser KN, Ruedinger B, Hyngstrom J, et al
   ASO Visual Abstract: National Evaluation of the Management of Melanoma Patients with Multiple Positive Sentinel Lymph Nodes.
   Ann Surg Oncol. 2025 Nov 3. doi: 10.1245/s10434-025-18651.
   PubMed    
   
   
   
5. ROBINSON TP, Kaiser KN, Ruedinger B, Hyngstrom J, et al
   National Evaluation of the Management of Melanoma Patients with Multiple Positive Sentinel Lymph Nodes.
   Ann Surg Oncol. 2025 Nov 1. doi: 10.1245/s10434-025-18466.
   PubMed     Abstract available
   
   
   October 2025
6. FARIES MB, Hieken TJ
   Clinical Stage II Melanoma: Is There a "Simple Trick" to Significantly Improve Event-Free Survival?
   Ann Surg Oncol. 2025 Oct 30. doi: 10.1245/s10434-025-18616.
   PubMed    
   
   
   
7. VAN AKKOOI ACJ
   Melanoma 2.0: Time to Move Beyond Breslow Thickness?
   Ann Surg Oncol. 2025 Oct 20. doi: 10.1245/s10434-025-18591.
   PubMed    
   
   
   
8. NOVIS E, Rautalin M, Amaria RN, Ascierto PA, et al
   International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma.
   Ann Surg Oncol. 2025 Oct 14. doi: 10.1245/s10434-025-18475.
   PubMed     Abstract available
   
   
   
9. SWILLING AC, Selby LV
   Axillary Sentinel Lymph Node Biopsy for Cutaneous Melanoma: More Work Is Not Needed.
   Ann Surg Oncol. 2025 Oct 13. doi: 10.1245/s10434-025-18443.
   PubMed    
   
   
   
10. SHAFIQUE N, Farooq MS, Mattfeld V, Vargas GM, et al
    ASO Visual Abstract: Single-Dose Neoadjuvant Pembrolizumab in Resectable Metastatic Melanoma.
    Ann Surg Oncol. 2025 Oct 8. doi: 10.1245/s10434-025-18507.
    PubMed    
    
    
    September 2025
11. MADDINENI S, Dizon MP, Muralidharan V, Young LA, et al
    Correction: Validation of the Melanoma Institute of Australia's Sentinel Lymph Node Biopsy Risk Prediction Tool for Cutaneous Melanoma.
    Ann Surg Oncol. 2025 Sep 29. doi: 10.1245/s10434-025-18434.
    PubMed    
    
    
    
12. FAROOQ MS, Shafique N, Karakousis GC
    ASO Author Reflections: Single-Dose Neoadjuvant Pembrolizumab in Resectable Metastatic Melanoma.
    Ann Surg Oncol. 2025 Sep 29. doi: 10.1245/s10434-025-18456.
    PubMed    
    
    
    
13. PAPAI E, Ntoh K, Zhang L, Yu JQ, et al
    The Utility of Preoperative PET/CT in Patients with Clinically High-Risk Melanoma.
    Ann Surg Oncol. 2025 Sep 25. doi: 10.1245/s10434-025-18096.
    PubMed     Abstract available
    
    
    
14. FAROOQ MS, Karakousis GC
    ASO Author Reflections: Recurrence Patterns and Survival Outcomes in Clinical Stage IIB/IIC Melanoma: Can We Stratify Patients for Consideration of Neoadjuvant Immunotherapy?
    Ann Surg Oncol. 2025 Sep 17. doi: 10.1245/s10434-025-18373.
    PubMed    
    
    
    
15. STOFF R, Yalon M, Thorpe MP, Flotte TJ, et al
    ASO Visual Abstract: Accuracy of PET-CT to Assess the Extent of Nodal Disease in Patients with Clinical Stage III Melanoma Following Neoadjuvant Treatment.
    Ann Surg Oncol. 2025 Sep 16. doi: 10.1245/s10434-025-18370.
    PubMed    
    
    
    
16. SHAFIQUE N, Farooq MS, Mattfeld V, Vargas GM, et al
    Single-Dose Neoadjuvant Pembrolizumab in Resectable Metastatic Melanoma.
    Ann Surg Oncol. 2025 Sep 12. doi: 10.1245/s10434-025-18314.
    PubMed     Abstract available
    
    
    
17. BICHAKJIAN CK, Swetter SM, Carroll BT, Vidal NY, et al
    ICEMAN (Intelligent Choice of Excision Margin): A Randomized Controlled Trial of Adaptive Narrow Excision Versus Wide Excision for Adults with AJCC Stage I Cutaneous Melanoma.
    Ann Surg Oncol. 2025 Sep 8. doi: 10.1245/s10434-025-18282.
    PubMed    
    
    
    
18. FAROOQ MS, Mattfeld V, Beniwal PC, Vargas GM, et al
    Recurrence Patterns and Survival Outcomes in Clinical Stage IIB/IIC Melanoma: Can We Stratify Patients for Consideration of Neoadjuvant Immunotherapy?
    Ann Surg Oncol. 2025 Sep 4. doi: 10.1245/s10434-025-18263.
    PubMed     Abstract available
    
    
    
19. PAPAI E, Ntoh K, Zhang L, Yu JQ, et al
    ASO Visual Abstract: The Utility of Preoperative PET/CT in Patients with Clinically High-Risk Melanoma.
    Ann Surg Oncol. 2025 Sep 3. doi: 10.1245/s10434-025-18266.
    PubMed    
    
    
    
20. TAYLOR CD, Niba VS, Baskin AS, Mott NM, et al
    ASO Visual Abstract: Evaluating Variation in Lymph Node Sampling During Sentinel Lymph Node Biopsy for Melanoma.
    Ann Surg Oncol. 2025 Sep 1. doi: 10.1245/s10434-025-18254.
    PubMed    
    
    
    August 2025
21. STOFF R, Block MS, Hieken TJ
    ASO Author Reflections: Is PET/CT Response Assessment After Neoadjuvant Systemic Therapy for Stage III Melanoma Enough?
    Ann Surg Oncol. 2025 Aug 29. doi: 10.1245/s10434-025-18276.
    PubMed    
    
    
    
22. VAN AKKOOI A, Ariyan C, Moncrieff M
    Melanoma Great Debate: Targeted Versus Complete Nodal Dissection Following Neoadjuvant Therapy for Melanoma: Is it Time to Push Forward or Hold Off on Continued De-Escalation of Surgery?
    Ann Surg Oncol. 2025 Aug 29. doi: 10.1245/s10434-025-18163.
    PubMed     Abstract available
    
    
    
23. STOFF R, Yalon M, Thorpe MP, Flotte TJ, et al
    Accuracy of PET-CT to Assess the Extent of Nodal Disease in Patients with Clinical Stage III Melanoma Following Neoadjuvant Treatment.
    Ann Surg Oncol. 2025 Aug 26. doi: 10.1245/s10434-025-18191.
    PubMed     Abstract available
    
    
    
24. ZAGER JS, John J
    Response to Letter to the Editor Regarding: An Open-Label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma.
    Ann Surg Oncol. 2025 Aug 21. doi: 10.1245/s10434-025-18092.
    PubMed    
    
    
    
25. TAYLOR CD, Niba VS, Baskin AS, Mott NM, et al
    Evaluating Variation in Lymph Node Sampling During Sentinel Lymph Node Biopsy for Melanoma.
    Ann Surg Oncol. 2025 Aug 16. doi: 10.1245/s10434-025-18063.
    PubMed     Abstract available
    
    
    July 2025
26. FAZAL T, Mustaan A, Fazal S, Raham F, et al
    An Open-Label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma.
    Ann Surg Oncol. 2025 Jul 29. doi: 10.1245/s10434-025-18020.
    PubMed    
    
    
    
27. ZAGER JS, John J
    ASO Visual Abstract: An Open-Label, Randomized Study of Melphalan/Hepatic Delivery System versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma.
    Ann Surg Oncol. 2025 Jul 15. doi: 10.1245/s10434-025-17726.
    PubMed    
    
    
    
28. PAZHAVA A, Yu WY, Jing FZ, Hill S, et al
    Correction: Enhanced Risk Stratification for Sentinel Lymph Node Biopsy in Head and Neck Melanoma Using the Merlin Assay (CP-GEP).
    Ann Surg Oncol. 2025 Jul 12. doi: 10.1245/s10434-025-17805.
    PubMed    
    
    
    June 2025
29. DUGAN MM, Boby A, Ghali H, Aflatooni S, et al
    ASO Visual Abstract: Isolated Limb Infusion or Perfusion as First-Line Versus Second-Line Therapy for In-Transit Metastatic Melanoma.
    Ann Surg Oncol. 2025 Jun 20. doi: 10.1245/s10434-025-17560.
    PubMed    
    
    
    
30. ORME SE, Moncrieff MD, Saldanha G
    ASO Author Reflections: Novel 2D Histopathological Markers for the Risk Stratification of Sentinel Node Metastasis in the Era of Adjuvant Systemic Therapy for Primary Cutaneous Melanoma.
    Ann Surg Oncol. 2025 Jun 19. doi: 10.1245/s10434-025-17610.
    PubMed    
    
    
    
31. ORME SE, Bamford M, O'Riordan M, Da Forno PD, et al
    ASO Visual Abstract: Validation of Invasive Area for Predicting Sentinel Node Status and Survival in Primary Cutaneous Melanoma.
    Ann Surg Oncol. 2025 Jun 17. doi: 10.1245/s10434-025-17576.
    PubMed    
    
    
    
32. KIM J, Lee DY, Mun GH, Lee KT, et al
    ASO Visual Abstract: Association of Weight-Bearing Activity and Prognosis of Plantar Melanoma-An Unanticipated Perspective.
    Ann Surg Oncol. 2025 Jun 14. doi: 10.1245/s10434-025-17623.
    PubMed    
    
    
    
33. ZAGER JS, John J
    ASO Author Reflections: Percutaneous Hepatic Perfusion with Melphalan/Hepatic Delivery System Versus Best Alternative Care for Patients with Metastatic Uveal Melanoma.
    Ann Surg Oncol. 2025 Jun 12. doi: 10.1245/s10434-025-17614.
    PubMed    
    
    
    
34. DUGAN MM, Israeli J, Chin N, Balsay-Patel C, et al
    ASO Visual Abstract: Isolated Limb Infusion/Perfusion for Unresectable Acral versus Non-Acral Melanoma In-Transit Metastases.
    Ann Surg Oncol. 2025 Jun 4. doi: 10.1245/s10434-025-17636.
    PubMed    
    
    
    May 2025
35. NOVIS E, Tan J, Vignati D, Wong T, et al
    ASO Visual Abstract: Cartilage Resection in the Surgical Management of Ear Melanoma.
    Ann Surg Oncol. 2025 May 28. doi: 10.1245/s10434-025-17495.
    PubMed    
    
    
    
36. DUGAN MM, Israeli J, Olofsson Bagge R, Zager JS, et al
    ASO Author Reflections: Outcomes after Treatment with Isolated Limb Infusion or Perfusion for Acral versus Non-Acral Melanoma In-Transit Metastases.
    Ann Surg Oncol. 2025 May 26. doi: 10.1245/s10434-025-17544.
    PubMed    
    
    
    
37. DUGAN MM, Israeli J, Chin N, Balsay-Patel C, et al
    Isolated Limb Infusion/Perfusion for Unresectable Acral Versus Non-Acral Melanoma In-Transit Metastases.
    Ann Surg Oncol. 2025 May 24. doi: 10.1245/s10434-025-17490.
    PubMed     Abstract available
    
    
    
38. ORME SE, Bamford M, O'Riordan M, Da Forno PD, et al
    Validation of Invasive Area for Predicting Sentinel Node Status and Survival in Primary Cutaneous Melanoma.
    Ann Surg Oncol. 2025 May 23. doi: 10.1245/s10434-025-17442.
    PubMed     Abstract available
    
    
    
39. DUGAN MM, Beekman KE, DePalo DK, Parker LM, et al
    ASO Visual Abstract: The Use of Radar-Guided Localization to Identify Metastatic Melanoma After Neoadjuvant Immunotherapy.
    Ann Surg Oncol. 2025 May 23. doi: 10.1245/s10434-025-17504.
    PubMed    
    
    
    
40. DUGAN MM, Olofsson Bagge R, Zager JS
    Correction: ASO Author Reflections: Management of Melanoma In-Transit Metastasis with Isolated Limb Infusion or Perfusion as First-Line versus Second-Line Therapy.
    Ann Surg Oncol. 2025 May 21. doi: 10.1245/s10434-025-17597.
    PubMed    
    
    
    
41. RHODIN KE, O'Connor MH, Therien A, Hollander S, et al
    ASO Visual Abstract: Circulating Tumor DNA in High-Risk Stage II/III Cutaneous Melanoma: A Feasibility Study.
    Ann Surg Oncol. 2025 May 11. doi: 10.1245/s10434-025-17411.
    PubMed    
    
    
    
42. DUGAN MM, Boby A, Ghali H, Aflatooni S, et al
    Isolated Limb Infusion or Perfusion as First-Line Versus Second-Line Therapy for In-Transit Metastatic Melanoma.
    Ann Surg Oncol. 2025 May 10. doi: 10.1245/s10434-025-17403.
    PubMed     Abstract available
    
    
    
43. DUGAN MM, Beekman KE, Zager JS
    ASO Author Reflections: Successful Radar-Guided Localization for Targeted Melanoma Metastasectomy After Neoadjuvant Immunotherapy.
    Ann Surg Oncol. 2025 May 9. doi: 10.1245/s10434-025-17427.
    PubMed    
    
    
    
44. DUGAN MM, Bagge RO, Zager JS
    ASO Author Reflections: Management of Melanoma In-Transit Metastasis with Isolated Limb Infusion or Perfusion as First-Line versus Second-Line Therapy.
    Ann Surg Oncol. 2025 May 7. doi: 10.1245/s10434-025-17461.
    PubMed    
    
    
    
45. PENNINGTON TE, Thompson JF, Saw RPM, Coker DJ, et al
    The Value of Sentinel Node Biopsy in Patients With Higher-Risk (T3, T4) Primary Cutaneous Melanomas: Insights Provided by a Stage II Risk Calculator.
    Ann Surg Oncol. 2025 May 2. doi: 10.1245/s10434-024-16699.
    PubMed    
    
    
    April 2025
46. NOVIS E, Tan J, Vignati D, Wong T, et al
    Cartilage Resection in the Surgical Management of Ear Melanoma.
    Ann Surg Oncol. 2025 Apr 28. doi: 10.1245/s10434-025-17294.
    PubMed     Abstract available
    
    
    
47. DUGAN MM, Beekman KE, DePalo DK, Parker LM, et al
    The Use of Radar-Guided Localization to Identify Metastatic Melanoma After Neoadjuvant Immunotherapy.
    Ann Surg Oncol. 2025 Apr 25. doi: 10.1245/s10434-025-17330.
    PubMed     Abstract available
    
    
    
48. MAHUMUD RA, Law CK, Ospino DA, de Wilt JHW, et al
    ASO Visual Abstract: Economic Evaluation of Inguinal Versus Ilio-inguinal Lymphadenectomy for Patients with Stage III Metastatic Melanoma to Groin Lymph Node: Evidence from the EAGLE FM Randomized Trial.
    Ann Surg Oncol. 2025 Apr 20. doi: 10.1245/s10434-025-17169.
    PubMed    
    
    
    
49. MASPERO M, Pezzoli I, Di Guardo L, Angi M, et al
    Intention-to-Treat Analysis of Hepatic Resection for Liver Metastases from Uveal Melanoma: A Single-Center Experience.
    Ann Surg Oncol. 2025 Apr 17. doi: 10.1245/s10434-025-17115.
    PubMed     Abstract available
    
    
    
50. MAHUMUD RA, Law CK, Ospino DA, de Wilt JHW, et al
    Correction: Economic Evaluation of Inguinal Versus Ilio-inguinal Lymphadenectomy for Patients with Stage III Metastatic Melanoma to Groin Lymph Nodes: Evidence from the EAGLE FM Randomized Trial.
    Ann Surg Oncol. 2025 Apr 16. doi: 10.1245/s10434-025-17337.
    PubMed    
    
    
    
51. ZAGER JS, Orloff M, Ferrucci PF, Choi J, et al
    An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma.
    Ann Surg Oncol. 2025 Apr 7. doi: 10.1245/s10434-025-17231.
    PubMed     Abstract available
    
    
    March 2025
52. RHODIN KE, O'Connor MH, Therien A, Hollander S, et al
    Circulating Tumor DNA in High-Risk Stage II/III Cutaneous Melanoma: A Feasibility Study.
    Ann Surg Oncol. 2025 Mar 27. doi: 10.1245/s10434-025-17194.
    PubMed     Abstract available
    
    
    
53. GONZALES M, Grosh K, Coster S, Hunt A, et al
    ASO Visual Abstract: Morbidity of Sentinel Lymph Node Biopsy in Melanoma Patients Better Defined.
    Ann Surg Oncol. 2025 Mar 23. doi: 10.1245/s10434-025-17139.
    PubMed    
    
    
    
54. RHODIN KE, O'Connor MH, Beasley GM
    ASO Author Reflections: Circulating Tumor DNA in High-Risk Resected Melanoma: Is there a Role?
    Ann Surg Oncol. 2025 Mar 18. doi: 10.1245/s10434-025-17223.
    PubMed    
    
    
    
55. ASARE EA
    Long Live the Sentinel Lymph Node Biopsy in Primary Cutaneous Melanoma.
    Ann Surg Oncol. 2025 Mar 18. doi: 10.1245/s10434-025-17181.
    PubMed    
    
    
    
56. VAN DOREN AS, Shah H, Ata A, Davis L, et al
    ASO Visual Abstract: An Evaluation of Sentinel Lymph Node Biopsy Guideline Adherence in Melanoma.
    Ann Surg Oncol. 2025 Mar 11. doi: 10.1245/s10434-025-17135.
    PubMed    
    
    
    
57. LOWE MC, Delman KA, Ollila DW
    The Landmark Series: Melanoma and Adjuvant Therapy.
    Ann Surg Oncol. 2025 Mar 11. doi: 10.1245/s10434-025-17102.
    PubMed    
    
    
    
58. HUIBERS A, Leong SP, Kashani-Sabet M, White RL Jr, et al
    Identification of Predictive Factors for the Development of In-Transit Metastasis in Patients with Melanoma.
    Ann Surg Oncol. 2025 Mar 10. doi: 10.1245/s10434-025-17084.
    PubMed     Abstract available
    
    
    
59. RIAZ N, Huibers A, Leong SP, Kashani-Sabet M, et al
    ASO Visual Abstract: Prognostic Value of Nevus-Associated Melanoma in Patients with Melanoma.
    Ann Surg Oncol. 2025 Mar 8. doi: 10.1245/s10434-025-17078.
    PubMed    
    
    
    
60. STEADMAN JA, Day CN, Hieken TJ
    Baseline Compliance with Commission on Cancer Standard 5.5: Wide Local Excision for Primary Cutaneous Melanoma.
    Ann Surg Oncol. 2025 Mar 3. doi: 10.1245/s10434-025-17046.
    PubMed    
    
    
    
61. DREBIN HM, Kurtansky NR, Hosein S, Nadelmann E, et al
    Declining Clinical Utility of Tools for Predicting Sentinel Lymph Node Biopsy Status: A Single Institution Experience from 2000 to 2021.
    Ann Surg Oncol. 2025;32:1463-1472.
    PubMed     Abstract available
    
    
    February 2025
62. DAVIS L, Van Doren AS
    ASO Author Reflections: Sentinel Lymph Node Biopsy Performance Rates in Cutaneous Melanoma.
    Ann Surg Oncol. 2025 Feb 28. doi: 10.1245/s10434-025-17094.
    PubMed    
    
    
    
63. MAHUMUD RA, Law CK, Ospino DA, de Wilt JHW, et al
    Economic Evaluation of Inguinal Versus Ilio-inguinal Lymphadenectomy for Patients with Stage III Metastatic Melanoma to Groin Lymph Nodes: Evidence from the EAGLE FM Randomized Trial.
    Ann Surg Oncol. 2025 Feb 27. doi: 10.1245/s10434-025-17040.
    PubMed     Abstract available
    
    
    
64. RIAZ N, Olofsson Bagge R
    ASO Author Reflections: Nevus-Associated Melanoma: A Prognostically Distinct Entity.
    Ann Surg Oncol. 2025 Feb 18. doi: 10.1245/s10434-025-16999.
    PubMed    
    
    
    
65. GONZALES M, Grosh K, Coster S, Hunt A, et al
    Better-Defined Morbidity of Sentinel Lymph Node Biopsy in Patients with Melanoma.
    Ann Surg Oncol. 2025 Feb 13. doi: 10.1245/s10434-025-16987.
    PubMed     Abstract available
    
    
    
66. VAN DOREN AS, Shah H, Ata A, Davis L, et al
    An Evaluation of Sentinel Lymph Node Biopsy Guideline Adherence in Melanoma.
    Ann Surg Oncol. 2025 Feb 7. doi: 10.1245/s10434-025-16971.
    PubMed     Abstract available
    
    
    
67. YOON CH, Ross MI, Gastman BR, Luke JJ, et al
    Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial.
    Ann Surg Oncol. 2025 Feb 1. doi: 10.1245/s10434-024-16642.
    PubMed     Abstract available
    
    
    
68. RIAZ N, Huibers A, Leong SP, Kashani-Sabet M, et al
    Prognostic Value of Nevus-Associated Melanoma in Patients with Melanoma.
    Ann Surg Oncol. 2025 Feb 1. doi: 10.1245/s10434-025-16945.
    PubMed     Abstract available
    
    
    January 2025
69. PAZHAVA A, Yu WY, Jing FZ, Hill S, et al
    Correction: Enhanced Risk Stratification for Sentinel Lymph Node Biopsy in Head and Neck Melanoma Using the Merlin Assay (CP-GEP).
    Ann Surg Oncol. 2025 Jan 30. doi: 10.1245/s10434-025-16946.
    PubMed    
    
    
    December 2024
70. LEE AH, Nessim C
    ASO Author Reflections: Do Biopsy Margins Really Matter in Melanoma?
    Ann Surg Oncol. 2024 Dec 31. doi: 10.1245/s10434-024-16804.
    PubMed    
    
    
    
71. PAZHAVA A, Yu WY, Jing FZ, Hill S, et al
    ASO Visual Abstract: Enhanced Risk Stratification for Sentinel Lymph Node Biopsy in Head and Neck Melanoma Using the Merlin Assay (CP-GEP).
    Ann Surg Oncol. 2024 Dec 30. doi: 10.1245/s10434-024-16798.
    PubMed    
    
    
    
72. MIURA JT, Karakousis GC
    Neoadjuvant Nivolumab and Ipilimumab for Resectable Stage III Melanoma: The New Standard of Care?
    Ann Surg Oncol. 2024 Dec 29. doi: 10.1245/s10434-024-16807.
    PubMed    
    
    
    
73. PENNINGTON TE, Thompson JF, Varey AHR
    ASO Author Reflections: Is Sentinel Node Biopsy Still of Value for Patients with High-Risk Primary Melanomas Eligible for Adjuvant Immunotherapy?
    Ann Surg Oncol. 2024 Dec 27. doi: 10.1245/s10434-024-16821.
    PubMed    
    
    
    
74. DREBIN HM, Kurtansky NR, Marchetti MA, Bartlett EK, et al
    ASO Author Reflections: Eroding Utility of Prognostic Tools for Melanoma Sentinel Lymph Node Metastasis During Two Decades.
    Ann Surg Oncol. 2024 Dec 26. doi: 10.1245/s10434-024-16771.
    PubMed    
    
    
    
75. KIM J, Lee DY, Mun GH, Lee KT, et al
    Association of Weight-Bearing Activity and Prognosis of Plantar Melanoma: An Unanticipated Perspective.
    Ann Surg Oncol. 2024 Dec 23. doi: 10.1245/s10434-024-16740.
    PubMed     Abstract available
    
    
    
76. MONTGOMERY KB, Chandler McLeod M, DePalo DK, Dugan MM, et al
    ASO Visual Abstract: Impact of Social Determinants of Health on Melanoma Nodal Surveillance in a Multi-Institutional Cohort.
    Ann Surg Oncol. 2024 Dec 11. doi: 10.1245/s10434-024-16690.
    PubMed    
    
    
    
77. SIERRA-DAVIDSON K, Dedeilia A, Lawless A, Sharova T, et al
    ASO Visual Abstract: Genetic Factors Associated with Clinical Response in Melanoma Patients Treated with Talimogene Laherparepvec-A Single-Institution Retrospective Analysis.
    Ann Surg Oncol. 2024 Dec 9. doi: 10.1245/s10434-024-16487.
    PubMed    
    
    
    
78. MONTGOMERY KB, Broman KK
    ASO Author Reflections: Investigating Social Risk Factors for Melanoma Nodal Surveillance Adherence in Real-World Populations.
    Ann Surg Oncol. 2024 Dec 9. doi: 10.1245/s10434-024-16683.
    PubMed    
    
    
    November 2024
79. MEVES A
    ASO Author Reflections: From SLNB to Neoadjuvant Therapy: How CP-GEP Might Help Shape the Future of Melanoma Treatment.
    Ann Surg Oncol. 2024 Nov 29. doi: 10.1245/s10434-024-16615.
    PubMed    
    
    
    
80. PAZHAVA A, Yu WY, Jing FZ, Hill S, et al
    Enhanced Risk Stratification for Sentinel Lymph Node Biopsy in Head and Neck Melanoma Using the Merlin Assay (CP-GEP).
    Ann Surg Oncol. 2024 Nov 23. doi: 10.1245/s10434-024-16551.
    PubMed     Abstract available
    
    
    
81. MONTGOMERY KB, McLeod MC, DePalo DK, Dugan MM, et al
    Impact of Social Determinants of Health on Melanoma Nodal Surveillance in a Multi-institutional Cohort.
    Ann Surg Oncol. 2024 Nov 22. doi: 10.1245/s10434-024-16498.
    PubMed     Abstract available
    
    
    
82. LEE A, Wong B, Li H, Grose E, et al
    ASO Visual Abstract: Are Positive Biopsy Margins in Melanoma Significant? A Cohort Study of Micro- Versus Macroscopic Margin Status and Their Impact on Residual Disease and Survival.
    Ann Surg Oncol. 2024 Nov 14. doi: 10.1245/s10434-024-16434.
    PubMed    
    
    
    
83. FARMA JM, Olszanski AJ, Messina JL, Sondak VK, et al
    Annals of Surgical Oncology Practice Guidelines Series: Adjuvant and Neoadjuvant Therapy for Melanoma.
    Ann Surg Oncol. 2024 Nov 4. doi: 10.1245/s10434-024-16418.
    PubMed     Abstract available
    
    
    October 2024
84. HIEKEN TJ, Ariyan C
    Personalized mRNA Vaccines and Contemporary Melanoma Practice.
    Ann Surg Oncol. 2024 Oct 31. doi: 10.1245/s10434-024-15731.
    PubMed    
    
    
    
85. BARTLETT EK, O'Donoghue C, Boland G, Bowles T, et al
    Society of Surgical Oncology Consensus Statement: Assessing the Evidence for and Utility of Gene Expression Profiling of Primary Cutaneous Melanoma.
    Ann Surg Oncol. 2024 Oct 29. doi: 10.1245/s10434-024-16379.
    PubMed     Abstract available
    
    
    
86. SIERRA-DAVIDSON K, Dedeilia A, Lawless A, Sharova T, et al
    Genetic Factors Associated with Clinical Response in Melanoma Patients Treated with Talimogene Laherparapvec: A Single-Institution Retrospective Analysis.
    Ann Surg Oncol. 2024 Oct 18. doi: 10.1245/s10434-024-16346.
    PubMed     Abstract available
    
    
    
87. LEE A, Wong B, Li H, Grose E, et al
    Are Positive Biopsy Margins in Melanoma Significant?: A Cohort Study of Micro- Versus Macroscopic Margin Status and Their Impact on Residual Disease and Survival.
    Ann Surg Oncol. 2024 Oct 9. doi: 10.1245/s10434-024-16301.
    PubMed     Abstract available
    
    
    
88. GHALI H, Dugan MM, Aflatooni S, Boby A, et al
    ASO Visual Abstract: Hepatic and Overall Progression-Free Survival After Percutaneous Hepatic Perfusion as First- or Second-Line Therapy for Metastatic Uveal Melanoma.
    Ann Surg Oncol. 2024 Oct 8. doi: 10.1245/s10434-024-16307.
    PubMed    
    
    
    
89. RHODIN KE, Beasley G
    Reply to: "Methodological Concerns Regarding: "Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?"" by Ahlstrom.
    Ann Surg Oncol. 2024 Oct 5. doi: 10.1245/s10434-024-16299.
    PubMed    
    
    
    September 2024
90. ROJAS-GARCIA P, Ma B, Jonsson EL, Genereux O, et al
    ASO Visual Abstract: Using Nomograms Wisely-Predicting Sentinel Node Positivity in Melanoma.
    Ann Surg Oncol. 2024 Sep 21. doi: 10.1245/s10434-024-16074.
    PubMed    
    
    
    August 2024
91. GHALI H, Dugan MM, Zager JS
    ASO Author Reflections: Optimizing Line of Therapy with the Melphalan/Hepatic Delivery System for Metastatic Uveal Melanoma.
    Ann Surg Oncol. 2024 Aug 28. doi: 10.1245/s10434-024-16112.
    PubMed    
    
    
    
92. GHALI H, Dugan MM, Aflatooni S, Boby A, et al
    Hepatic and Overall Progression-Free Survival After Percutaneous Hepatic Perfusion (PHP) as First-Line or Second-Line Therapy for Metastatic Uveal Melanoma.
    Ann Surg Oncol. 2024 Aug 22. doi: 10.1245/s10434-024-16039.
    PubMed     Abstract available
    
    
    
93. AHLSTROM MG
    Methodological Concerns Regarding: "Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?".
    Ann Surg Oncol. 2024 Aug 17. doi: 10.1245/s10434-024-15944.
    PubMed    
    
    
    
94. ZIEGLER-RODRIGUEZ G, De La Cruz-Ku G, Piedra-Delgado L, Torres-Maldonado J, et al
    Correction: Unveiling Melanoma: A Deep Dive into Disparities at a Latin-American Cancer Institute.
    Ann Surg Oncol. 2024 Aug 14. doi: 10.1245/s10434-024-16062.
    PubMed    
    
    
    
95. ROJAS-GARCIA P, Ma B, Jonsson EL, Genereux O, et al
    Using Nomograms Wisely: Predicting Sentinel Node Positivity in Melanoma.
    Ann Surg Oncol. 2024 Aug 13. doi: 10.1245/s10434-024-15891.
    PubMed     Abstract available
    
    
    
96. KAKISH H, Jung CA, Doh SJ, Mulligan KM, et al
    ASO Visual Abstract: The Utility of Sentinel Lymph Node Biopsy in Elderly Patients with Melanoma.
    Ann Surg Oncol. 2024 Aug 7. doi: 10.1245/s10434-024-15828.
    PubMed    
    
    
    July 2024
97. MONTGOMERY KB, Duncan ZN, Holder AM, Burgan CM, et al
    ASO Visual Abstract: Interdisciplinary Implementation of a Synoptic Reporting Template for Melanoma Nodal Surveillance Ultrasound.
    Ann Surg Oncol. 2024 Jul 29. doi: 10.1245/s10434-024-15959.
    PubMed    
    
    
    
98. KAKISH H, Rothermel LD
    ASO Author Reflections: The Association Between Sentinel Lymph Node Biopsy and Melanoma-Specific Survival in the Elderly.
    Ann Surg Oncol. 2024 Jul 26. doi: 10.1245/s10434-024-15785.
    PubMed    
    
    
    
99. KAKISH H, Jung CA, Doh SJ, Mulligan KM, et al
    The Utility of Sentinel Lymph Node Biopsy in Elderly Patients with Melanoma.
    Ann Surg Oncol. 2024 Jul 22. doi: 10.1245/s10434-024-15684.
    PubMed     Abstract available
    
    
    
100. ZAGER JS, Orloff M, Ferrucci PF, Choi J, et al
     Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
     Ann Surg Oncol. 2024 Jul 18. doi: 10.1245/s10434-024-15886.
     PubMed    
     
     
     
101. MONTGOMERY KB, Holder AM, Broman KK
     ASO Author Reflections: Synoptic Reporting for Melanoma Nodal Surveillance Ultrasonography.
     Ann Surg Oncol. 2024 Jul 16. doi: 10.1245/s10434-024-15735.
     PubMed    
     
     
     
102. ZIEGLER-RODRIGUEZ G, De La Cruz Ku G, Piedra-Delgado L, Torres-Maldonado J, et al
     ASO Visual Abstract: Unveiling Melanoma-A Deep Dive Into Disparities at a Latin-American Cancer Institute.
     Ann Surg Oncol. 2024 Jul 10. doi: 10.1245/s10434-024-15755.
     PubMed    
     
     
     
103. EGGER ME, McMasters KM
     Finally! An Improved Prognostic Calculator for Cutaneous Melanoma.
     Ann Surg Oncol. 2024 Jul 6. doi: 10.1245/s10434-024-15763.
     PubMed    
     
     
     
104. WINDER AA, Boyer Z, Ch'ng S, Stretch JR, et al
     ASO Visual Abstract: Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas.
     Ann Surg Oncol. 2024 Jul 3. doi: 10.1245/s10434-024-15636.
     PubMed    
     
     
     
105. ZIEGLER-RODRIGUEZ G, Ziegler-Rodriguez O, De La Cruz-Ku G, Cotrina-Concha JM, et al
     ASO Author Reflections: Distilling Wisdom From Two Decades of Cutaneous Malignant Melanoma at a Peruvian Cancer Institute: A Stirring Call for Action.
     Ann Surg Oncol. 2024 Jul 2. doi: 10.1245/s10434-024-15672.
     PubMed    
     
     
     
106. KFIR U, Ronen O
     Intraparotid Sentinel Lymph Node Dissection for Melanoma: A Systematic Review and Meta-Analysis.
     Ann Surg Oncol. 2024 Jul 2. doi: 10.1245/s10434-024-15668.
     PubMed     Abstract available
     
     
     
107. MONTGOMERY KB, Duncan ZN, Holder AM, Burgan CM, et al
     Interdisciplinary Implementation of a Synoptic Reporting Template for Melanoma Nodal Surveillance Ultrasound.
     Ann Surg Oncol. 2024 Jul 2. doi: 10.1245/s10434-024-15630.
     PubMed     Abstract available
     
     
     June 2024
108. PINKHAM MB, Herschtal A, Hong AM, Chua MS, et al
     ASO Author Reflections: The Role of Postoperative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck: Now and into the Future.
     Ann Surg Oncol. 2024 Jun 24. doi: 10.1245/s10434-024-15657.
     PubMed    
     
     
     
109. LWIN TM, Kaelberer Z, Ruan M, Molina G, et al
     Correction: Surgical Utilization and Outcomes for Patients with Stage IV Melanoma in the Modern Immunotherapy Era.
     Ann Surg Oncol. 2024 Jun 23. doi: 10.1245/s10434-024-15641.
     PubMed    
     
     
     
110. ZIEGLER-RODRIGUEZ G, De La Cruz-Ku G, Piedra-Delgado L, Torres-Maldonado J, et al
     Unveiling Melanoma: A Deep Dive into Disparities at a Latin-American Cancer Institute.
     Ann Surg Oncol. 2024 Jun 18. doi: 10.1245/s10434-024-15573.
     PubMed     Abstract available
     
     
     
111. WINDER AA, Spillane AJ, Smith AL
     ASO Author Reflections: Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas.
     Ann Surg Oncol. 2024 Jun 14. doi: 10.1245/s10434-024-15590.
     PubMed    
     
     
     
112. PINKHAM MB, Herschtal A, Hong AM, Chua MS, et al
     Randomized Trial of Postoperative Radiation Therapy After Wide Excision of Neurotropic Melanoma of the Head and Neck (RTN2 Trial 01.09).
     Ann Surg Oncol. 2024 Jun 8. doi: 10.1245/s10434-024-15569.
     PubMed     Abstract available
     
     
     May 2024
113. WINDER AA, Boyer Z, Ch'ng S, Stretch JR, et al
     Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas.
     Ann Surg Oncol. 2024 May 27. doi: 10.1245/s10434-024-15456.
     PubMed     Abstract available
     
     
     
114. ZAGER JS, Orloff M, Ferrucci PF, Choi J, et al
     ASO Visual Abstract: Efficacy and Safety of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter, Phase 3 Study.
     Ann Surg Oncol. 2024 May 24. doi: 10.1245/s10434-024-15421.
     PubMed    
     
     
     
115. LIANG C, Li D, Liang Y, Xie Y, et al
     ASO Visual Abstract: Prognostic and Predictive Significance of Ki67 in Primary Nonmetastatic or Recurrent Acral Melanoma-Evidence from a Multicenter Retrospective Study.
     Ann Surg Oncol. 2024 May 21. doi: 10.1245/s10434-024-15454.
     PubMed    
     
     
     
116. ZIJLKER LP, Chen H, Spillane AJ, Gonzalez M, et al
     The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort.
     Ann Surg Oncol. 2024 May 18. doi: 10.1245/s10434-024-15274.
     PubMed     Abstract available
     
     
     
117. ZIJLKER LP, Chen H, Spillane AJ, Gonzalez M, et al
     ASO Visual Abstract: The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma: An Australian Cohort.
     Ann Surg Oncol. 2024 May 17. doi: 10.1245/s10434-024-15348.
     PubMed    
     
     
     
118. GREENE AC, Ziegler O, Quattrone M, Stack MJ, et al
     ASO Visual Abstract: Association Between Medicaid Expansion and Cutaneous Melanoma Diagnosis and Outcomes-Does Where You Live Make a Difference?
     Ann Surg Oncol. 2024 May 14. doi: 10.1245/s10434-024-15343.
     PubMed    
     
     
     
119. ZAGER JS, Orloff M, Ferrucci PF, Choi J, et al
     Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
     Ann Surg Oncol. 2024 May 4. doi: 10.1245/s10434-024-15293.
     PubMed     Abstract available
     
     
     April 2024
120. LIANG C, Li D, Liang Y, Xie Y, et al
     Prognostic and Predictive Significance of Ki67 in Primary Non-metastatic or Recurrent Acral Melanoma: Evidence from a Multicenter Retrospective Study.
     Ann Surg Oncol. 2024 Apr 30. doi: 10.1245/s10434-024-15327.
     PubMed     Abstract available
     
     
     
121. GREENE AC, Ziegler O, Pameijer CR, Shen C, et al
     ASO Author Reflections: Exploring the Impact-Medicaid Expansion and Improved Survival in Patients with Cutaneous Melanoma.
     Ann Surg Oncol. 2024 Apr 22. doi: 10.1245/s10434-024-15286.
     PubMed    
     
     
     
122. LEE TS, Li I, Peric B, Saw RPM, et al
     ASO Visual Abstract: Leg Lymphoedema After Inguinal and Ilio-Inguinal Lymphadenectomy for Melanoma: Results from a Prospective Randomized Trial.
     Ann Surg Oncol. 2024 Apr 18. doi: 10.1245/s10434-024-15262.
     PubMed    
     
     
     March 2024
123. GREENE AC, Ziegler O, Quattrone M, Stack MJ, et al
     Association between Medicaid Expansion and Cutaneous Melanoma Diagnosis and Outcomes: Does Where You Live Make a Difference?
     Ann Surg Oncol. 2024 Mar 29. doi: 10.1245/s10434-024-15214.
     PubMed     Abstract available
     
     
     
124. LEE TS, Spillane AJ
     ASO Author Reflections: Lymphoedema Related to Inguinal and Ilioinguinal Lymphadenectomy for Melanoma.
     Ann Surg Oncol. 2024 Mar 27. doi: 10.1245/s10434-024-15216.
     PubMed    
     
     
     
125. LEE TS, Li I, Peric B, Saw RPM, et al
     Leg Lymphoedema After Inguinal and Ilio-Inguinal Lymphadenectomy for Melanoma: Results from a Prospective, Randomised Trial.
     Ann Surg Oncol. 2024 Mar 17. doi: 10.1245/s10434-024-15149.
     PubMed     Abstract available
     
     
     February 2024
126. MENSAH JA, Fei-Zhang DJ, Rossen JL, Rahmani B, et al
     Assessment of Social Vulnerabilities of Care and Prognosis in Adult Ocular Melanomas in the US.
     Ann Surg Oncol. 2024 Feb 28. doi: 10.1245/s10434-024-15038.
     PubMed     Abstract available
     
     
     
127. MADDINENI S, Dizon MP, Muralidharan V, Young LA, et al
     ASO Visual Abstract: Validation of the Melanoma Institute of Australia's Sentinel Lymph Node Biopsy Risk Prediction Tool for Cutaneous Melanoma.
     Ann Surg Oncol. 2024 Feb 5. doi: 10.1245/s10434-024-14996.
     PubMed    
     
     
     
128. DEDEILIA A, Lwin T, Li S, Tarantino G, et al
     ASO Visual Abstract: Factors Affecting Recurrence and Survival in High-Risk Stage II Melanoma.
     Ann Surg Oncol. 2024 Feb 1. doi: 10.1245/s10434-023-14869.
     PubMed    
     
     
     January 2024
129. ROSHAN A, Shah B, Anderson KD, Murphy S, et al
     ASO Visual Abstract: Robot-Assisted Pelvic Dissection for Enlarged Lymph Nodes in Melanoma Improves Recovery with Equivalent Oncological Outcomes to Open Pelvic Dissection.
     Ann Surg Oncol. 2024 Jan 22. doi: 10.1245/s10434-024-14920.
     PubMed    
     
     
     
130. MADDINENI S, Dizon MP, Muralidharan V, Young LA, et al
     Validation of the Melanoma Institute of Australia's Sentinel Lymph Node Biopsy Risk Prediction Tool for Cutaneous Melanoma.
     Ann Surg Oncol. 2024 Jan 12. doi: 10.1245/s10434-023-14862.
     PubMed     Abstract available
     
     
     
131. ROSHAN A, Shah B, Anderson KD, Murphy S, et al
     Robot-Assisted Pelvic Dissection for Enlarged Lymph Nodes in Melanoma Improves Recovery with Equivalent Oncological Outcomes to Open Pelvic Dissection.
     Ann Surg Oncol. 2024 Jan 4. doi: 10.1245/s10434-023-14834.
     PubMed     Abstract available
     
     
     December 2023
132. DEDEILIA A, Lwin T, Li S, Tarantino G, et al
     Factors Affecting Recurrence and Survival for Patients with High-Risk Stage II Melanoma.
     Ann Surg Oncol. 2023 Dec 29. doi: 10.1245/s10434-023-14724.
     PubMed     Abstract available
     
     
     
133. GJORUP CA, Woodford R, Li I, Carlino MS, et al
     ASO Visual Abstract: Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging.
     Ann Surg Oncol. 2023 Dec 20. doi: 10.1245/s10434-023-14665.
     PubMed    
     
     
     
134. BEASLEY GM, Terando AM
     Articles from 2022 to 2023 to Inform Your Cancer Practice: Melanoma.
     Ann Surg Oncol. 2023 Dec 10. doi: 10.1245/s10434-023-14702.
     PubMed     Abstract available
     
     
     
135. GJORUP CA, van Akkooi ACJ
     ASO Author Reflections: Recurrence in Sentinel Node-Positive Node Fields in Melanoma Patients Undergoing Surveillance Is More Common outside the Node Field.
     Ann Surg Oncol. 2023 Dec 4. doi: 10.1245/s10434-023-14623.
     PubMed    
     
     
     November 2023
136. SU D, Kluger H, Olino K
     Educational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma.
     Ann Surg Oncol. 2023 Nov 21. doi: 10.1245/s10434-023-14587.
     PubMed     Abstract available
     
     
     
137. GJORUP CA, Woodford R, Li I, Carlino MS, et al
     Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging.
     Ann Surg Oncol. 2023 Nov 15. doi: 10.1245/s10434-023-14526.
     PubMed     Abstract available
     
     
     October 2023
138. VAN AKKOOI ACJ
     Relatlimab, an Immune Checkpoint Inhibitor that Blocks LAG-3, the Latest Drug to be Added to the Arsenal of Systemic Therapies for Melanoma: What Does a Surgical Oncologist Need to Know?
     Ann Surg Oncol. 2023 Oct 16. doi: 10.1245/s10434-023-14416.
     PubMed    
     
     
     September 2023
139. HOLDER AM, Wargo JA, Ross MI
     Correction: Timing is Everything: Neoadjuvant Versus Adjuvant Immunotherapy in Patients with Resectable Metastatic Melanoma.
     Ann Surg Oncol. 2023 Sep 3. doi: 10.1245/s10434-023-14252.
     PubMed    
     
     
     August 2023
140. KESMODEL SB, Kronenfeld JP, Zhao W, Koru-Sengul T, et al
     ASO Visual Abstract: Omission of Completion Lymph Node Dissection in Sentinel Node Biopsy Positive Head and Neck Cutaneous Melanoma Patients.
     Ann Surg Oncol. 2023 Aug 31. doi: 10.1245/s10434-023-14183.
     PubMed    
     
     
     
141. KESMODEL SB, Kronenfeld JP, Zhao W, Koru-Sengul T, et al
     Omission of Completion Lymph Node Dissection in Sentinel Node Biopsy Positive Head and Neck Cutaneous Melanoma Patients.
     Ann Surg Oncol. 2023 Aug 28. doi: 10.1245/s10434-023-14036.
     PubMed     Abstract available
     
     
     
142. HOLMBERG CJ, Mikiver R, Isaksson K, Ingvar C, et al
     ASO Visual Abstract: Prognostic Significance of Sentinel Lymph Node Status in Thick Primary Melanomas (> 4 mm).
     Ann Surg Oncol. 2023 Aug 21. doi: 10.1245/s10434-023-14106.
     PubMed    
     
     
     
143. HOLDER AM, Wargo JA, Ross MI
     Timing is Everything: Neoadjuvant Versus Adjuvant Immunotherapy in Patients with Resectable Metastatic Melanoma.
     Ann Surg Oncol. 2023 Aug 19. doi: 10.1245/s10434-023-14133.
     PubMed    
     
     
     
144. SKITZKI JJ
     The Argument for Performing Sentinel Lymph Node Biopsy in Thick Primary Melanomas.
     Ann Surg Oncol. 2023 Aug 17. doi: 10.1245/s10434-023-14148.
     PubMed    
     
     
     
145. RHODIN KE, Jung SH, Elleson K, DePalo D, et al
     ASO Visual Abstract: Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does It Matter?
     Ann Surg Oncol. 2023 Aug 14. doi: 10.1245/s10434-023-14089.
     PubMed    
     
     
     
146. HOLMBERG CJ, Mikiver R, Isaksson K, Ingvar C, et al
     Prognostic Significance of Sentinel Lymph Node Status in Thick Primary Melanomas (> 4 mm).
     Ann Surg Oncol. 2023 Aug 14. doi: 10.1245/s10434-023-14050.
     PubMed     Abstract available
     
     
     
147. BATENI SB, Sutradhar R, Everett K, Wright FC, et al
     ASO Visual Abstract: The Association Between Pregnancy Timing and Cumulative Exposure on Survival in Melanoma.
     Ann Surg Oncol. 2023 Aug 5. doi: 10.1245/s10434-023-13995.
     PubMed    
     
     
     July 2023
148. GERSHENWALD JE
     Top Melanoma Articles from 2021 to Inform Your Cancer Practice.
     Ann Surg Oncol. 2023 Jul 26. doi: 10.1245/s10434-023-13853.
     PubMed     Abstract available
     
     
     
149. RHODIN KE, Jung SH, Elleson K, DePalo D, et al
     Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?
     Ann Surg Oncol. 2023 Jul 22. doi: 10.1245/s10434-023-13935.
     PubMed     Abstract available
     
     
     
150. RHODIN KE, Tyler DS, Zager JS, Beasley GM, et al
     Great Debate: Limb Infusion for Melanoma: A Thing of the Past?
     Ann Surg Oncol. 2023 Jul 17. doi: 10.1245/s10434-023-13765.
     PubMed    
     
     
     
151. PRIETO PA, Goldberg MS, Martin B
     RE: A Clinical Decision Tool to Calculate Pretest Probability of Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.
     Ann Surg Oncol. 2023 Jul 3. doi: 10.1245/s10434-023-13812.
     PubMed    
     
     
     June 2023
152. BATENI SB, Sutradhar R, Everett K, Wright FC, et al
     The Association Between Pregnancy Timing and Cumulative Exposure on Survival in Melanoma.
     Ann Surg Oncol. 2023 Jun 29. doi: 10.1245/s10434-023-13819.
     PubMed     Abstract available
     
     
     
153. TRIPATHI R, Larson K, Fowler G, Vetto JT, et al
     The Role of Clinicopathologic Nomograms for Melanoma in the Era of Gene Expression Profiling.
     Ann Surg Oncol. 2023 Jun 27. doi: 10.1245/s10434-023-13814.
     PubMed    
     
     
     
154. SHARON CE, Tortorello GN, Ma K, Sinnamon AJ, et al
     Impact of Adjuvant Immunotherapy on Overall Survival in a Contemporary Cohort of Patients with Stage III Melanoma.
     Ann Surg Oncol. 2023 Jun 19. doi: 10.1245/s10434-023-13736.
     PubMed    
     
     
     
155. FARIES MB, Lowe M
     Metastasectomy in Stage IV Melanoma: How and When Should We Employ It?
     Ann Surg Oncol. 2023 Jun 16. doi: 10.1245/s10434-023-13760.
     PubMed    
     
     
     
156. MONTGOMERY KB, Holder AM, Burgan CM, Galgano SJ, et al
     Is it Time for Synoptic Reporting in Melanoma Nodal Surveillance Ultrasonography?
     Ann Surg Oncol. 2023 Jun 16. doi: 10.1245/s10434-023-13749.
     PubMed    
     
     
     May 2023
157. LWIN TM, Kaelberer Z, Ruan M, Molina G, et al
     ASO Visual Abstract: Surgical Utilization and Outcomes for Patients with Stage 4 Melanoma in the Modern Immunotherapy Era.
     Ann Surg Oncol. 2023 May 29. doi: 10.1245/s10434-023-13611.
     PubMed    
     
     
     
158. LWIN T, Molina G, Boland G
     ASO Author Reflections: The Evolution of Surgery for Patients with Stage IV Melanoma.
     Ann Surg Oncol. 2023 May 24. doi: 10.1245/s10434-023-13646.
     PubMed     Abstract available
     
     
     
159. ESSNER R, Keller J
     Regarding: "Predicting Regional Lymph Node Recurrence in the Modern Age of Tumor-Positive Sentinel Node Melanoma," by Faries, Mark et al.
     Ann Surg Oncol. 2023 May 12. doi: 10.1245/s10434-023-13573.
     PubMed    
     
     
     
160. THOMPSON JF, Hyngstrom J, Caraco C, Zager JS, et al
     Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma.
     Ann Surg Oncol. 2023 May 6. doi: 10.1245/s10434-023-13570.
     PubMed    
     
     
     
161. SCHOENFELDT T, Chakera AH, Nieweg OE, Thompson JF, et al
     ASO Author Reflections: The Clinical Relevance of Sentinel Nodes in Minor Lymph Node Fields Such as the Triangular Intermuscular Space in Patients with Melanoma.
     Ann Surg Oncol. 2023 May 3. doi: 10.1245/s10434-023-13443.
     PubMed    
     
     
     
162. LWIN TM, Kaelberer Z, Ruan M, Molina G, et al
     Surgical Utilization and Outcomes for Patients with Stage IV Melanoma in the Modern Immunotherapy Era.
     Ann Surg Oncol. 2023 May 1. doi: 10.1245/s10434-023-13543.
     PubMed     Abstract available
     
     
     April 2023
163. GREENE AC, Wong WG, Perez Holguin RA, Patel A, et al
     ASO Visual Abstract: The Association of Guideline-Concordant Sentinel Lymph Node Biopsy for Melanoma at Minority-Serving Hospitals.
     Ann Surg Oncol. 2023 Apr 28. doi: 10.1245/s10434-023-13491.
     PubMed    
     
     
     
164. FADEL MG, Rauf S, Mohamed HS, Yusuf S, et al
     ASO Visual Abstract: The Use of Indocyanine Green and Near-Infrared Fluorescence Imaging Versus Blue Dye in Sentinel Lymph Node Biopsy in Cutaneous Melanoma: A Retrospective, Cohort Study.
     Ann Surg Oncol. 2023 Apr 21. doi: 10.1245/s10434-023-13479.
     PubMed    
     
     
     
165. FADEL MG, Rauf S, Mohamed HS, Yusuf S, et al
     The Use of Indocyanine Green and Near-Infrared Fluorescence Imaging Versus Blue Dye in Sentinel Lymph Node Biopsy in Cutaneous Melanoma: A Retrospective, Cohort Study.
     Ann Surg Oncol. 2023 Apr 16. doi: 10.1245/s10434-023-13405.
     PubMed     Abstract available
     
     
     
166. TRIPATHI R, Larson K, Fowler G, Han D, et al
     ASO Visual Abstract: A Clinical Decision Tool to Calculate Pretest Probability of Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.
     Ann Surg Oncol. 2023 Apr 15. doi: 10.1245/s10434-023-13410.
     PubMed    
     
     
     
167. SENDERS ZJ, Bartlett EK, Mouw TJ, McMasters KM, et al
     ASO Visual Abstract: Does Stage Migration Occur as a Consequence of Omitting Completion Lymph Node Dissection for Melanoma?
     Ann Surg Oncol. 2023 Apr 12. doi: 10.1245/s10434-023-13439.
     PubMed    
     
     
     
168. FADEL MG, Smith MJ
     ASO Author Reflections: Comparison of Indocyanine Green with Blue Dye in Sentinel Lymph Node Biopsy for Cutaneous Melanoma.
     Ann Surg Oncol. 2023 Apr 4. doi: 10.1245/s10434-023-13423.
     PubMed    
     
     
     March 2023
169. GREENE AC, Wong WG, Pameijer CR, Shen C, et al
     ASO Author Reflections: Lower Guideline Concordance and Decreased Overall Survival for Melanoma Patients at Minority-Serving Hospitals: How Can We Do Better?
     Ann Surg Oncol. 2023 Mar 30. doi: 10.1245/s10434-023-13377.
     PubMed    
     
     
     
170. GREENE AC, Wong WG, Perez Holguin RA, Patel A, et al
     The Association of Guideline-Concordant Sentinel Lymph Node Biopsy for Melanoma at Minority-Serving Hospitals.
     Ann Surg Oncol. 2023 Mar 19. doi: 10.1245/s10434-023-13341.
     PubMed     Abstract available
     
     
     
171. SENDERS ZJ, Bartlett EK, Mouw TJ, McMasters KM, et al
     Does Stage Migration Occur as a Consequence of Omitting Completion Lymph Node Dissection for Melanoma?
     Ann Surg Oncol. 2023 Mar 19. doi: 10.1245/s10434-023-13342.
     PubMed     Abstract available
     
     
     February 2023
172. TRIPATHI R, Larson K, Fowler G, Han D, et al
     A Clinical Decision Tool to Calculate Pretest Probability of Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.
     Ann Surg Oncol. 2023 Feb 25:1-8. doi: 10.1245/s10434-023-13220.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.